Skip to main content
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
Published Web Location
http://europepmc.org/articles/PMC4402449?pdf=renderNo data is associated with this publication.
Abstract
© Cancer Research UK Background:Simultaneous chemotherapy with vascular endothelial growth factor (VEGF) inhibition has not shown additional benefit over chemotherapy alone in advanced melanoma. We tested administration of the potent VEGF inhibitor axitini
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.